Abstract: The present invention relates to nonhuman transgenic animals exhibiting major disorders related to Alzheimer's disease. The animals can be used for demonstrating compounds intended for the treatment of Alzheimer's disease.
Abstract: The invention provides methods for analyzing heparins, low-molecular-weight heparins, ultralow-molecular-weight heparins, and oligosaccharides by high performance liquid chromatography a stationary phase dynamically coated with a quaternary ammonium salt. The methods of the invention may be used to analyze samples without pre-treatment or to analyze samples that have been partially or exhaustively depolymerised and, optionally, reduced. Specific saccharides can be detected.
Abstract: The invention concerns a novel method for preparing an intermediate polyanion for preparing cyclosporin derivatives by treating a cyclosporin with a hexamethyldisilazane metal salt, optionally in the presence of a metal halide. The treated cyclosporin has one or several free hydroxy groups and/or non-methylated nitrogen atoms in position ? and/or any other acid group capable of deprotonation which are optionally deprotonated or in protected form.
Abstract: The present invention relates to genetically modified yeast strains autonomously producing, from a simple carbon source, steroids. The invention also relates to a method for producing steroids from such yeast strains.
Type:
Grant
Filed:
January 29, 2002
Date of Patent:
March 2, 2010
Assignee:
Aventis Pharma S.A.
Inventors:
Roberto Spagnoli, Tilman Achstetter, Gilles Cauet, Eric Degryse, Bruno Dumas, Denis Pompon, Jacques Winter
Abstract: The invention relates to novel cytotoxic agents comprising taxanes and their therapeutic use as a result of delivering the taxanes to a specific cell population in a targeted fashion by chemically linking the taxane to a cell binding agent.
Type:
Grant
Filed:
December 6, 2005
Date of Patent:
February 23, 2010
Assignee:
Aventis Pharma S.A.
Inventors:
Michael L. Miller, Ravi V. J. Chari, Erkan Baloglu, Alain Commercon
Abstract: Composition intended for the oral administration of active principles with unacceptable taste, which comprises from about 15% to about 30% of organoleptically unpleasant active ingredient (principle) that is mixed with from about 60% to about 80% of an ester of glycerol or of a fatty acid, to which a wax is optionally added and to which a surfactant is added, and in that it is prepared by a spray-cooling process which can produce a particle size of less than 350 ?m.
Abstract: The invention relates to new heterocyclic compounds of general formula (I), and their salts with a base or an acid: The invention also relates to a process for the preparation of these compounds as well as their use as medicaments, in particular as anti-bacterial agents.
Type:
Grant
Filed:
September 14, 2005
Date of Patent:
December 29, 2009
Assignee:
Aventis Pharma S.A.
Inventors:
Maxime Lampilas, Jozsef Aszodi, David Alan Rowlands, Claude Fromentin
Abstract: The invention especially relates to novel chemical compounds, especially novel benzothiazole derivatives, to compositions containing said compounds, and to the use thereof as medicaments.
Type:
Grant
Filed:
September 29, 2006
Date of Patent:
December 15, 2009
Assignee:
Aventis Pharma S.A.
Inventors:
Stéphanie Deprets, Anke Steinmetz, Odile Angouillant-Boniface, Daniel Bezard, Jidong Zhang, Yannick Benedetti, François Clerc
Abstract: The present invention relates to a method for detecting leptin receptor ligands by measuring the energy transfer between fusion proteins comprising a leptin receptor and an energy donor protein or an energy acceptor acceptor protein proteins. The present invention also relates to fusion proteins for implementing said method.
Type:
Grant
Filed:
April 9, 2007
Date of Patent:
November 17, 2009
Assignees:
Aventis Pharma S.A., Institut de la Sante et de la Recherche Medicale Scientifique, Centre National de la Recherche
Abstract: The present invention relates to novel variants of the PapM polypeptide of bacteria of the Streptomyces genus which possess a substrate selectivity and/or an improved effectiveness compared to the wild-type polypeptide. It also relates to the nucleic acids encoding these variants, to the microorganisms which incorporate these nucleic acids and to their use for producing B components of Streptogramins.
Abstract: The disclosure relates to compounds of formula (I): wherein R1, R2, and R3 are as defined in the disclosure, compositions comprising said compounds, methods for their preparation, intermediates thereto, and the use thereof, particularly as medicaments.
Abstract: The present invention concerns hydrazinocarbonyl-thieno[2,3-c]pyrazoles of formula (I): wherein R1, R3, R4, are R5 are as defined in the disclosure; their preparation method, compositions containing the same and their use for the treatment of pathological conditions, in particular as anticancer agents.
Abstract: The invention concerns the production of cholesterol in organisms of the Fungi kingdom. More particularly, the invention concerns genetically modified Fungus independently producing cholesterol from a simple carbon source. The invention also concerns the use of the inventive Fungus for producing non-marked and marked cholesterol.
Type:
Application
Filed:
May 2, 2005
Publication date:
September 24, 2009
Applicant:
Aventis Pharma S.A.
Inventors:
Denis Pompon, Bruno Dumas, Roberto Spagnoli
Abstract: The disclosure concerns substituted pyrroles of formula (I): wherein A, L, Ar, R1, R2, R5, and Ra are as defined in the disclosure, compositions containing the same, methods for making the same and uses thereof, in particular as anti-cancer agents.
Type:
Grant
Filed:
August 1, 2007
Date of Patent:
September 22, 2009
Assignee:
Aventis Pharma S.A.
Inventors:
Baptiste Ronan, Michel Tabart, Catherine Souaille, Fabrice Viviani, Eric Bacque, Jean-Philippe Letallec, Pascal Desmazeau
Abstract: Novel compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein R, R1, R2, R3, R4, R5, and R6 have the meanings given in the description, pharmaceutical compositions comprising said compounds and use thereof as protein kinase inhibitors.
Abstract: The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which is quite specific. It also relates to novel chemical compounds as well as their therapeutic application in humans.
Type:
Application
Filed:
December 16, 2008
Publication date:
September 10, 2009
Applicant:
AVENTIS PHARMA S.A.
Inventors:
Patrick MAILLIET, Abdelazize LAOUI, Jean-Francois RIOU, Gilles DOERFLINGER, Jean-Louis MERGNY, Francois HAMY, Thomas CAULFIELD
Abstract: This invention discloses and claims methods for inhibiting bacterial ?-lactamases and treating bacterial infections by inhibiting bacterial ?-lactamases in man or an animal comprising administering a therapeutically effective amount to said man or said animal of a compound, or pharmaceutically acceptable salt thereof, of formula (I) either alone or in combination with a ?-lactamine antibiotic wherein said combination can be administered separately, together or spaced out over time. Pharmaceutical compositions comprising a compound of formula (I), or a combination of a compound of formula (I) and a therapeutically effective amount of a ?-lactamine antibiotic, and a pharmaceutically acceptable carrier are also disclosed and claimed.
Type:
Application
Filed:
May 1, 2009
Publication date:
August 27, 2009
Applicant:
Aventis Pharma S.A.
Inventors:
Jozsef Aszodi, Claude Fromentin, Maxime Lampilas, David Alan Rowlands
Abstract: The present invention relates to the isolation and identification of novel genes of the biosynthetic pathway for spiramycins and to novel polypeptides involved in this biosynthesis. The invention also relates to a method for producing these polypeptides. It also relates to the use of these genes for the purpose of increasing the levels of production and the purity of the spiramycin produced. The invention relates in particular to a microorganism which produces spiramycin I but which does not produce spiramycin II and III, and to the use of such a microorganism. The invention also relates to the use of the genes of the biosynthetic pathway for spiramycins for constructing mutants which can lead to the synthesis of novel antibiotics or to derived forms of spiramycins. The invention also relates to the molecules produced through the expression of these genes and to pharmacologically active compositions of a molecule produced through the expression of such genes.
Type:
Grant
Filed:
October 7, 2003
Date of Patent:
August 25, 2009
Assignees:
Aventis Pharma S., Centre National de la Recherche Scientifique
Inventors:
Marie-Helene Blondelet-Rouault, Helene Dominguez, Emmanuelle Darbon-Rongere, Claude Gerbaud, Anne Gondran, Fatma Karray, Patricia Lacroix, Nathalie Oestreicher-Mermet-Bouvier, Pernodet Jean-Luc, Karine Tuphile
Abstract: The present invention concerns DNA sequences from the K. lactis PGK gene having transcriptional promoter activity. to expression vectors comprising these sequences and to their use for the production of proteins.